BioPharmSignal logoBioPharmSignal

Biotech News

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Atea (AVIR)AteaConference / presentation

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD,

Related news

AVIRAtea2026-01-06 12:00 EST

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

AVIRAtea2026-01-08 12:00 EST

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-01-05 12:00 EST

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ASMBAssembly Biosciences2026-05-11 12:00 EST

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

ANTXAN2 Therapeutics2026-02-17 12:00 EST

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

IMNNImunon2026-07-23 13:25 EST

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

COCPCocrystal Pharma2026-02-19 13:00 EST

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

View all latest news

Atea

Antiviral Therapeutics Company Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases. Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C. Global Phase 3 Program C-BEYOND covers...

Recent company news

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

AVIRAtea2026-07-28 11:00 EST

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

AVIRAtea2026-06-25 11:00 EST

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

AVIRAtea2026-05-27 11:00 EST

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Stock data

Close
4.99 USD
Market cap
341.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States